"I have patients increasingly coming to me saying, 'I hear it's not as expensive to get the pharmaceutical-grade branded version, can we switch over?'" said Dr. Michael Weintraub, assistant clinical professor of endocrinology at NYU Langone in New York.

Novo Nordisk believes that by marketing such untested medicines, Hims & Hers is exposing patients to drugs that may contain dangerous impurities or incorrect amounts of active ingredients, resulting in life-jeopardizing immune reactions.

The 1st U.S. Circuit Court of Appeals on Feb. 19 upheld a lower court's dismissal in 2025 of the class-action complaint filed in 2024, in which plaintiff Jamie Whittemore alleged that Cigna denied coverage of her doctor's prescription for Zepbound to treat obesity.